[{"reason": "The infant's jaundice is most likely physiological, as it peaks around the third to fifth day of life and resolves on its own typically by two weeks.", "option": "C", "e_context": "The jaundice level of 18 mg/dL, along with a healthy feeding pattern and no signs of illness, aligns with the expected presentation of physiological neonatal jaundice resulting from immature liver function."}, {"reason": "The patient is at substantial risk for acquiring HIV due to his sexual history and partners. The use of PrEP has been shown to be safe and effective for individuals engaged in high-risk sexual behaviors, significantly reducing the risk of HIV acquisition when taken consistently.", "option": "B", "e_context": "Daily oral PrEP with the fixed-dose combination of tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg has been shown to be safe and effective in reducing the risk of sexual HIV acquisition in adults; therefore, PrEP is recommended as one prevention option for sexually-active adult MSM (men who have sex with men) at substantial risk of HIV acquisition."}, {"reason": "Adherence to PrEP is crucial for its efficacy, but when combined with other risk-reduction strategies, patients have a higher chance of preventing HIV acquisition.", "option": "D", "e_context": "Because high medication adherence is critical to PrEP efficacy but was not uniformly achieved by trial participants, patients should be encouraged and enabled to use PrEP in combination with other effective prevention methods."}, {"reason": "This infant's symptoms\u2014delayed walking, bowlegged appearance, tenderness over the ribs and skull, and being exclusively breastfed without vitamin D supplementation\u2014are indicative of rickets caused by vitamin D deficiency.", "option": "B", "e_context": "Rickets leads to softening and weakening of the bones, resulting in deformities, which aligns with the findings observed in the clinical scenario."}, {"reason": "The efficacy of PrEP has been well-established in clinical trials, demonstrating significant reductions in HIV infection rates among at-risk populations.", "option": "B", "e_context": "Recent findings from several clinical trials have demonstrated safety and a substantial reduction in the rate of HIV acquisition for men who have sex with men (MSM), men and women in heterosexual HIV-discordant couples, and heterosexual men and women recruited as individuals who were prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)."}, {"reason": "Given the patient's high-risk behavior, daily oral PrEP with TDF/FTC is recommended as an effective preventive measure for individuals at substantial risk of HIV acquisition.", "option": "B", "e_context": "Currently, prescribing daily oral PrEP with TDF/FTC is recommended as one prevention option for MSM, heterosexual men, heterosexual women, and IDU at substantial risk of HIV acquisition."}, {"reason": "Pre-exposure prophylaxis (PrEP) has been shown to significantly reduce the risk of HIV acquisition among individuals at high risk.", "option": "C", "e_context": "Evidence from these human studies of blood-borne and perinatal transmission as well as studies of vaginal and rectal exposure among animals suggested that PrEP (using antiretroviral drugs) could reduce the risk of acquiring HIV infection from sexual and drug-use exposures."}, {"reason": "Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) primarily work by inhibiting the reverse transcriptase enzyme, thereby preventing the conversion of viral RNA into DNA.", "option": "C", "e_context": "# IPREX (PREEXPOSURE PROPHYLAXIS INITIATIVE) TRIAL"}, {"reason": "The most immediate and effective intervention for improving outcomes in STEMI patients is the timely administration of thrombolytic therapy to restore perfusion to the occluded coronary artery.", "option": "B", "e_context": "This patient presents with signs indicative of an ST-elevation myocardial infarction (STEMI), characterized by ST-segment elevation on the ECG and chest pain."}, {"reason": "The study reported that back pain was the only significant adverse event associated with the use of TDF.", "option": "D", "e_context": "US MSM SAFETY TRIAL"}, {"reason": "By preventing HIV from establishing infection in the target cells.", "option": "C", "e_context": "No HIV infections occurred while participants were being given TDF; 3 occurred in men while taking placebo, 3 occurred among men in the delayed TDF group who had not started receiving drug."}, {"reason": "The Partners PrEP trial demonstrated that daily oral TDF/FTC is effective in preventing the acquisition of HIV among uninfected partners in HIV-discordant couples.", "option": "B", "e_context": "PUBLISHED TRIALS OF ANTIRETROVIRAL PREEXPOSURE PROPHYLAXIS AMONG HETEROSEXUAL MEN AND WOMEN"}, {"reason": "The new medication does not significantly alter the likelihood of developing the disease compared to the placebo.", "option": "B", "e_context": "The trial was stopped after an interim analysis in mid-2011 showed statistically significant efficacy in the medication groups (TDF/FTC or TDF) compared with the placebo group."}, {"reason": "This patient\u2019s symptoms of nausea and dizziness align with the reported side effects of TDF/FTC, with these symptoms being more common during the first month of use.", "option": "C", "e_context": "(10.3 per 100 person -years) and rates did not differ significantly between the study groups."}, {"reason": "Lack of statistical significance in the difference of HIV infection rates between treatment and placebo groups.", "option": "C", "e_context": "The trial was stopped when an interim analysis revealed that it was unlikely to detect a statistically significant difference in efficacy between the treatment group (TDF/FTC) and the placebo group regarding their HIV infection rates."}, {"reason": "The oral TDF and TDF/FTC groups showed no statistically significant effectiveness.", "option": "C", "e_context": "The trial was stopped in 2011, when an interim analysis determined that the trial would be unlikely to detect a statistically significant difference in efficacy between the two study groups."}, {"reason": "Implementing directly-observed therapy for medication adherence.", "option": "B", "e_context": "Of these women, 3,019 were randomly assigned to daily oral medication (TDF/FTC, 1,003; TDF, 1,007; oral placebo, 1,009). In 2011, the trial group receiving oral TDF and the group receiving topical tenofovir were stopped after interim analyses determined futility."}, {"reason": "TDF has shown a higher efficacy when adherence to the medication is high.", "option": "C", "e_context": "Daily oral PrEP with TDF/FTC is recommended as one HIV prevention option for heterosexually-active men and women at substantial risk of HIV acquisition because these trials present evidence of its safety and 2 present evidence of efficacy in these populations, especially when medication adherence is high."}, {"reason": "The supine sleeping position is the most effective way to prevent SIDS.", "option": "D", "e_context": "The study was conducted at drug treatment clinics; 22% of participants were receiving methadone treatment at baseline."}, {"reason": "This patient's sexual history and recent pregnancy scare, along with her lack of consistent condom use, puts her at risk for bacterial STIs such as chlamydia or gonorrhea.", "option": "A", "e_context": "as this can guide decisions around HIV exposure risk and the possible need for preventive measures like PrEP."}, {"reason": "PrEP is a recommended additional strategy to reduce the risk of HIV infection, especially for individuals with uncertain condom use and multiple sexual partners.", "option": "C", "e_context": "PrEP is effective when taken consistently and can provide significant protection against HIV in high-risk individuals, such as those with multiple partners or those who partner with HIV-positive individuals."}, {"reason": "The patient's history of intravenous drug use and current health threats highlight the importance of evaluating her risk for relapse into drug use.", "option": "C", "e_context": "In addition, if substance abuse is reported, the clinician should provide referral for appropriate treatment or harm-reduction services acceptable to the patient."}, {"reason": "The main purpose of HIV testing before starting PrEP is to ensure that the patient does not already have an HIV infection, as administering PrEP to someone who is already HIV-positive can lead to drug resistance and complicate treatment options.", "option": "B", "e_context": "A patient who reports that 1 or more regular sex partners is of unknown HIV status should be offered HIV testing for those partners..."}, {"reason": "This patient developed the M184V mutation because he likely had an undiagnosed acute HIV infection at the time PrEP was initiated.", "option": "C", "e_context": "individuals can develop drug-resistant strains when they begin antiretroviral therapy while already being acutely infected with HIV."}, {"reason": "Due to the patient\u2019s high-risk behavior as a sexually active man who has sex with men (MSM) and his lack of previous testing, it is crucial to test for HBV and HCV before starting PrEP with TDF/FTC.", "option": "B", "e_context": "The Centers for Disease Control and Prevention (CDC) and the US Preventive Services Task Force recommends that MSM, IDUs, patients with a sex partner who has HIV infection, and others at substantial risk of HIV acquisition undergo an HIV test at least annually..."}, {"reason": "TDF/FTC provides effective prophylaxis against HIV when taken as directed and is the recommended and FDA-approved regimen for PrEP in MSM.", "option": "A", "e_context": "In the iPrEx trial, drug-resistant virus developed in 2 persons with unrecognized acute HIV infection at enrollment and for whom TDF/FTC had been dispensed."}, {"reason": "Based on pharmacokinetic studies, maximum intracellular concentrations of TFV-DP in rectal tissue are reached after approximately 7 days of daily oral dosing.", "option": "B", "e_context": "This information is crucial for individuals considering PrEP to understand the time frame required for the medication to reach protective levels in tissues associated with potential HIV exposure."}, {"reason": "Conducting an HIV test and assessing for signs of acute infection is necessary to determine if an individual is at risk of acquiring HIV before prescribing PrEP.", "option": "A", "e_context": "The medication proven safe and effective, and currently approved by FDA for PrEP in healthy adults at risk of acquiring HIV infection..."}, {"reason": "Therapeutic drug monitoring is limited in PrEP because the medication levels in blood reflect only very recent doses, which do not provide an accurate estimate of long-term adherence.", "option": "C", "e_context": "The time from initiation of daily oral doses of TDF/FTC to maximal protection against HIV infection is unknown. There is not scientific consensus on what intracellular concentrations are protective for either drug or the protective contribution of each drug in specific body tissues."}, {"reason": "It is crucial to document the patient's HIV status to ascertain their need for further monitoring and ensure their safety after discontinuation of PrEP.", "option": "B", "e_context": "Repeat HIV testing and assess for signs or symptoms of acute infection to document that patients are still HIV negative."}, {"reason": "Having an undetectable viral load significantly minimizes the risk of sexual transmission of HIV.", "option": "C", "e_context": "These factors include (1) a lack of established concentrations in blood associated with robust efficacy of TDF or FTC for the prevention of HIV acquisition in adults after exposure during penile-rectal or penile-vaginal intercourse."}, {"reason": "The patient has tested positive for HBsAg, indicating active HBV infection. It is crucial to evaluate and manage his HBV infection before commencing PrEP.", "option": "C", "e_context": "For persons with active hepatitis B infection, see Special Clinical Considerations."}, {"reason": "PrEP is not recommended due to the patient's reduced renal function.", "option": "C", "e_context": "Providers should educate HIV-discordant couples who wish to become pregnant about the potential risks and benefits of all available alternatives for safer conception."}, {"reason": "Initiating nPEP within 72 hours is crucial in preventing potential HIV infection.", "option": "A", "e_context": "This patient is at risk due to the recent sexual assault, and initiating nPEP within 72 hours is crucial in preventing potential HIV infection."}, {"reason": "Incorporating the medication into her daily routine, such as taking it with a multivitamin, enhances the likelihood of adherence.", "option": "D", "e_context": "Aligning the medication-taking with an established habit can help to create a consistent routine, which is essential for successful long-term use of PrEP."}, {"reason": "Addressing the side effects directly is crucial for improving medication adherence.", "option": "B", "e_context": "Persons who repeatedly seek nPEP should be evaluated for possible PrEP use after confirming they have not acquired HIV infection."}, {"reason": "A broad health care team can address the diverse needs of patients by facilitating discussions about individual risk behaviors and providing tailored strategies that align with their specific circumstances.", "option": "B", "e_context": "Because PrEP will be used in otherwise healthy adults, studies of the use of medications in asymptomatic adults for the prevention of potential serious future health outcomes may also be informative for enhancing adherence to PrEP medications."}, {"reason": "Providing access to unused injection equipment through needle exchange programs has been shown to significantly reduce the risk of HIV exposure among individuals who continue to engage in injection drug use.", "option": "B", "e_context": "The importance of using condoms during sex, especially for patients who decide to stop taking their medications, should be reinforced."}, {"reason": "Implementing a phone reminder system to notify patients of their upcoming prescriptions and follow-up appointments.", "option": "B", "e_context": "This broad-team approach may also provide a larger number of providers to counsel patients about self-management of behavioral risks."}]